Lupin Digital Health, The American College of Cardiology collaborate to deliver in home cardiovascular care with Digital Therapeutics in India

As part of this collaboration, Lupin Digital Health will leverage ACC's CardioSmart platform, guidelines, and workbooks to guide healthcare professionals and caregivers.

Published On 2023-07-25 04:30 GMT   |   Update On 2023-07-25 12:07 GMT

Mumbai: Lupin Digital Health, India’s evidence-based cardiology digital therapeutics (DTx) platform and the American College of Cardiology (ACC), the global scientific leader in the practice of Cardiology, have announced a first-of-its-kind collaboration to deliver in-home cardiovascular care with Digital Therapeutics (DTx) in India. This collaboration aims to accelerate the application...

Login or Register to read the full article

Mumbai: Lupin Digital Health, India’s evidence-based cardiology digital therapeutics (DTx) platform and the American College of Cardiology (ACC), the global scientific leader in the practice of Cardiology, have announced a first-of-its-kind collaboration to deliver in-home cardiovascular care with Digital Therapeutics (DTx) in India. This collaboration aims to accelerate the application and adoption of DTx in Cardiology in India. Lupin Digital Health’s DTx platform, Lyfe, also aims to give patients and their healthcare providers tools to manage heart diseases at home and help to ensure patients stay healthy after hospital discharge and reduce rehospitalization.

India is grappling with a staggering burden of cardiovascular disease, predicted to have the highest number of cardiac deaths globally by 2030. As per the Indian Heart Association, heart diseases disproportionately affect Indians at a younger age, often without warning. Studies highlight that Indians suffer from heart ailments at least a decade earlier than their Western counterparts, underscoring the urgent need for preventive and comprehensive care.

This collaboration signifies a monumental leap in transforming cardiac care in India. As part of this collaboration, Lupin Digital Health will leverage ACC’s CardioSmart platform, guidelines, and workbooks to guide healthcare professionals and caregivers. These tools will be accessible to doctors, patients, and caregivers through Lupin Digital Health's Lyfe app and website, lyfe.in.

"This collaboration with Lupin Digital Health reflects our commitment to advancing equitable cardiovascular care globally and demonstrates how innovative collaborations can deliver transformative outcomes for patients in India," stated ACC Chief Innovation Officer Ami B. Bhatt, MD, FACC.

"India’s vast talent pool and widespread adoption of smartphone-based technology present immense potential for leveraging Digital Therapeutics. Our focus is on delivering practical solutions that empower doctors to provide superior patient care. Through our collaboration with ACC, we aim to revolutionize the management of heart disease in India, enabling healthcare professionals and caregivers to provide effective care to patients outside of hospitals,” stated Rajeev Sibal, President – India Region Formulations, Lupin Limited.

Emphasizing the patient-centric approach of the collaboration, Sidharth Srinivasan, CEO of Lupin Digital Health, said, "The mounting burden of cardiovascular disease in India, affecting even the younger generation, makes this collaboration an urgent imperative. Lupin Digital Health's unique value proposition lies in providing patients with the convenience of monitoring and rehabilitation, all from the comfort of their homes, while receiving comprehensive care from their treating cardiologists. This collaboration marks a significant milestone in the advancement of Digital Therapeutics in the field of cardiology in India."

To promote the adoption of advanced digital solutions in Cardiology, ACC will provide certificates to cardiologists, recognizing their dedication to innovation and patient-centric healthcare.

Read also: Lupin incorporates wholly owned subsidiary for neuro-rehabilitation business

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News